High-Sensitivity Cardiac Troponin I Is a Strong Predictor of Cardiovascular Events and Mortality in the AGES-Reykjavik Community-Based Cohort of Older Individuals.

• Published in: Clinical Chemistry
• Main Authors: Thorsteinsdottir, Ingunn, Aspelund, Thor, Gudmundsson, Elias, Eiriksdottir, Gudny, Harris, Tamara B, Launer, Lenore J, Gudnason, Vilmundur, Venge, Per
• Other Authors: 1 Iceland Heart Assoc, Res Inst, Kopavogur, Iceland 2 Landspitali Univ Hosp, Dept Clin Biochem, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital 3 Univ Iceland, Fac Med, Reykjavik, Iceland 4 NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA 5 Uppsala Univ, Dept Med Sci, Uppsala, Sweden
• Format: Article in Journal/Newspaper
• Language: English
• Published: Amer Assoc Clinical Chemistry 2016
• Subjects: Hjartasjúkdómar; Aldraðir; MAB12; Aged; 80 and over; Aging; Biomarkers; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Humans; Iceland; Incidence; Male; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Troponin I; Abbott
• Online Access: http://hdl.handle.net/2336/618496; https://doi.org/10.1373/clinchem.2015.250811

To access publisher's full text version of this article click on the hyperlink at the bottom of the page The objective of this study was to investigate the predictive power of a high-sensitivity cardiac troponin I (hs-cTnI) assay for cardiovascular events and mortality in a large population of older community dwellers. Blood was collected from 5764 individuals (age 66-98 years) during the period of 2002-2006 and the outcome as to all-cause death and incidence of cardiovascular disease (CVD) and coronary heart disease (CHD) followed up to 10 years. hs-cTnI (Abbott) was measured in serum to assess the association of this marker with CVD, CHD and death, and finally, to compare the results with conventional risk factors by multivariable statistical analysis. The median (interquartile range) concentrations of hs-cTnI were 8.4 ng/L (5.6-14.2 ng/L) and 5.3 ng/L (3.8-8.1 ng/L) in men (2416) and women (3275), respectively, and the concentrations increased linearly with age. Outcomes as to all-cause death and incidence of CVD and CHD were significantly associated with increasing concentrations of hs-cTnI beginning well below the 99th percentile concentrations. The associations with outcome remained after adjustments for conventional risk factors and were similar in men and women. Our findings suggest that hs-cTnI reflects the status of the myocardium even in seemingly healthy individuals and that the measurements of hs-cTnI may be useful for primary prediction of heart disease; this should form the basis for future prospective clinical trials for determining whether measuring hs-cTnI can be used in the prevention of CVD/CHD. National Institutes of Health, USA N01-AG-12100 National Institute on Aging Intramural Research Program, the National Eye Institute USA Z01-EY000401 National Institutes of Health Hjartavernd (the Icelandic Heart Association) Althingi (Icelandic Parliament) Abbott Diagnostics